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OBJECTIVES The purpose of the study was to assess the effect of lipid reduction with pravastatin on
hospital admissions in middle-aged men with hypercholesterolemia in the West of Scotland
Coronary Prevention Study.
BACKGROUND A prospective, randomized controlled trial was undertaken in primary care centers in the
West of Scotland.
METHODS A total of 6,595 participants randomized to receive pravastatin 40 mg or placebo daily were
followed up for a mean of 4.9 years (range 3.5 to 6.1 years). Analysis of hospital admissions
was undertaken according to the “intention to treat” principle both for cardiovascular diseases
and noncardiovascular diseases (including malignant neoplasms, psychiatric diagnoses,
trauma and other causes). A secondary analysis of hospitalization in patients who were $75%
compliant was performed.
RESULTS During the trial, 2,198 (33%) of the 6,595 men were admitted to hospital on 4,333 occasions,
of which 1,234 (28%) were for cardiovascular causes. Pravastatin reduced the number of
subjects requiring hospital admission for cardiovascular causes by 21% (95% CI [confidence
interval] 9 to 31, p 5 0.0008) overall, and by 27% (95% CI 15 to 38) in compliant
participants. The number of admissions per 1,000 subject-years for cardiovascular disease was
reduced by 10.8 (95% CI 4 to 17.4, p 5 0.0013) in all subjects, and by 15.6 (95% CI 8.3 to
23, p , 0.0001) in compliant participants. Pravastatin had no significant influence on hospital
admission for any noncardiovascular diagnostic category. There were 13.4 fewer admissions
per 1,000 subject-years for all causes in the pravastatin-treated group (95% CI 20.4 to 27.3,
p 5 0.076). No significant difference in duration of hospital stay was found between the
pravastatin and placebo patients in any diagnostic group.
CONCLUSIONS Pravastatin therapy reduced the burden of hospital admissions for cardiovascular disease,
without any adverse effect on noncardiovascular hospitalization. (J Am Coll Cardiol 1999;33:
909–15) © 1999 by the American College of Cardiology
The West of Scotland Coronary Prevention Study
(WOSCOPS) (1) demonstrated the benefit of pravastatin
therapy in the prevention of coronary heart disease (CHD)
events in middle-aged men with hypercholesterolemia
within prior myocardial infarction (MI). This result has
helped to end the long-running controversy over the safety
and efficacy of reducing plasma cholesterol levels in the
primary prevention of coronary events (2,3). Meta-analysis
of earlier studies using cholesterol-lowering diets, fibrates or
cholestyramine had raised the possibility that the reduction
in CHD deaths achieved by cholesterol lowering was
balanced by an increase in noncardiovascular deaths, partic-
ularly due to cancers, accidents, suicide or violence (3–5). In
contrast, the West of Scotland study showed no evidence of
excess noncardiovascular deaths either overall or from any
specific cause. This observation is reinforced by the absence
of any increase in noncardiovascular deaths in secondary
prevention trials using pravastatin or simvastatin (6,7). In
addition to assessment of mortality rates, analysis of nonfa-
tal events is also necessary in determining the overall
benefits and safety of lipid-lowering drug therapy. The
objective of the current analysis was to study the effects of
pravastatin therapy on morbidity as expressed by the re-
quirement for and duration of hospital admission in the
WOSCOPS.
METHODS
The design, baseline characteristics and principal results of
the WOSCOPS have been reported elsewhere (1,8,9). In
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brief, 6,595 men ages 45 to 64 years with low-density
lipoprotein levels in the range 4 to 6 mmol/liter (155 to
232 mg/dl) despite dietary therapy were recruited by pop-
ulation screening. The principal exclusion criteria were
previous MI or coronary revascularization, angina pectoris
requiring hospitalization within the previous 12 months and
life-threatening noncardiac illness. Participants with major
electrocardiographic (ECG) abnormalities such as Q-waves,
major ST-T abnormalities or left bundle branch block
(Minnesota Codes 1-1 to 1-3, 4-1, 5-1 or 7-1-1) were
excluded, but minor ST-T-wave changes (Codes 4-2, 4-3,
5-2, 5-3) were permitted. The presence of self-reported
angina pectoris or intermittent claudication as determined
by the Rose questionnaire was permitted, subject to the
exclusions mentioned.
Participants were randomized to receive either pravastatin
40 mg or a placebo each evening. They were followed up every
three months for a mean of 4.9 years (range 3.5 to 6.1 years),
giving a total of 32,216 subject-years of observation. The dates
of any hospital admission and discharge were obtained, with a
copy of the hospital discharge summary, which documents the
primary and secondary reasons for hospitalization.
Diagnoses were coded according to the International
Classification of Diseases 8th Revision (ICD 8) and proce-
dures according to the Office of Population Censuses and
Surveys Revision 4 Coding (OPCS 4). In addition to direct
reports of hospitalization from the trial participants, the
occurrence of hospital admission was verified from central
records using the Scottish Record Linkage System (10). We
previously validated the accuracy of this system compared
with hospital admission data obtained by direct patient
enquiry (11). By means of direct contact and record linkage,
we were able to obtain details of hospitalization both for
subjects remaining in the trial and for those who had
withdrawn from trial therapy and follow-up attendance.
The study protocol was approved by the local research ethics
committees in the West of Scotland.
Statistical methods. The primary analysis of hospital ad-
missions was undertaken according to the “intention to
treat” principle. Among cardiovascular causes for hospital-
ization, we determined separately admissions for atheroscle-
rotic CHD, nonatherosclerotic heart disease, cerebrovascu-
lar disease and other vascular disease. Noncardiovascular
hospital admissions were analyzed under the trial categories
of malignancy (including lymphoma, myeloma and malig-
nant melanoma but excluding minor skin cancers), psychi-
atric diagnoses, trauma and other causes. An individual may
have experienced one or more hospital admissions for
diagnoses within a given category, as well as admissions for
problems in one or more categories. We also performed a more
detailed cause-specific analysis of noncardiovascular hospital
admissions based on the ICD 8 body systems classification.
We previously reported the influence of compliance on
the reduction in coronary risk in subjects receiving prava-
statin (12). A secondary analysis of the hospitalization data
was performed for compliant patients, defined as in the
previous report as those attending and being issued with
trial medication at $75% of potential trial visits.
The intervals from randomization to first hospital admission
for both cardiovascular and noncardiovascular categories were
compared among treatment groups using the log-rank test and
displayed as Kaplan-Meier plots. Comparisons among treat-
ment groups of the proportion of subjects hospitalized were
made using chi-square statistics and corresponding confidence
intervals (CI) for risk ratios. The comparisons involving num-
ber of admissions and total days hospitalized were made using
permutation tests. Approximate 95% CI for the differences in
rates of these outcomes were calculated from the mean differ-
ences 6 1.96 standard error (SE). For those participants who
were hospitalized, the duration of stay was compared among
the treatment groups using a Wilcoxon rank-sum test.
To compare admission rates with respect to underlying
risk of coronary events, participants were categorized ac-
cording to quartiles of baseline five-year untreated risk of
definite CHD death or nonfatal MI. These were calculated
using a Cox proportional hazards survival model incorpo-
rating smoking, diabetes mellitus, nitrate consumption,
angina pectoris, family history of CHD, widowhood, age,
diastolic blood pressure and total/HDL (high density li-
poprotein) cholesterol ratio, as previously reported (13). The
numbers of patients admitted within each quartile for each
treatment group were compared using the Fisher exact test.
Differences in the effect of pravastatin across the quartiles
were tested using a logistic regression model incorporating
treatment, risk quartiles and their interactions. Statistical
calculations were performed using SAS 6.12 for Windows.
Results are presented (unless otherwise indicated) as
numbers of participants, numbers of admissions or total
days hospitalized per 1,000 subject-years. The observed
number of subjects, admissions or total days hospitalized can
be recovered by multiplying the rates presented by the observed
duration of follow-up in subject years and dividing by 1,000.
RESULTS
Duration of follow-up. In the primary analysis, there were
15,766 treatment-years of observed follow up in 3,293
placebo-treated participants and 15,909 treatment-years in
3,302 pravastatin-treated patients.
Abbreviations and Acronyms
CHD 5 coronary heart disease
CI 5 confidence interval
ICD 8 5 International Classification of Diseases
8th Revision
MI 5 myocardial infarction
OPCS 4 5 Office of Population Censuses and
Surveys Revision 4 coding
WOSCOPS 5 West of Scotland Coronary Prevention
Study
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Number of trial subjects hospitalized. During the trial,
2,198 (33%) of the 6,595 men were admitted to hospital on
one or more occasions. Cardiovascular disease was the
principal cause of admission in 736 individuals. The number
of participants (per 1,000) requiring hospitalization accord-
ing to trial category is listed in Table 1, and the Kaplan-
Meier curves for time to first cardiovascular and noncardio-
vascular admissions are illustrated in Figure 1A and B,
respectively. Pravastatin reduced the number of participants
requiring hospital admission for CHD by 29% (95% CI 16
to 41, p , 0.0001), and for all cardiovascular causes by 21%
(95% CI 9 to 31, p 5 0.0008). There was no significant
difference between treatment groups in the number of
subjects or time to first hospitalization for noncardiovascular
causes.
Number of hospital admissions. Among the 2,198 partic-
ipants admitted to hospital in the study, there was a total of
4,333 hospital admissions, a median of one (interquartile
range [IQR] 1 to 2, range 1 to 29) per participant. Of all
hospital admissions, 1,234 (28%) were for cardiovascular
causes. Pravastatin reduced the number of admissions per
1,000 subject-years for atherosclerotic CHD by 9.3 (95% CI
4 to 14.6, p 5 0.0008), and for all cardiovascular causes by
10.8 (95% CI 4 to 17.4, p 5 0.0013). There were no
significant differences in the number of admissions due to
malignant neoplasms, trauma or psychiatric causes, and no
significant impact on the overall risk of hospital admission
for noncardiovascular causes (Table 2 and Fig. 2). In total,
there were 13.4 fewer hospital admissions per 1,000 subject-
years for all causes in the pravastatin-treated group (95% CI
20.4 to 27.3, p 5 0.076).
The number of hospital admissions for noncardiovascular
diagnoses was analyzed in more detail according to major
body systems using the primary ICD 8 code (Fig. 2). The
only significant differences in hospital admission rates be-
Table 1. Effect of Pravastatin on Hospital Admissions by Trial Category
Trial Category
Number of Subjects Number of Admissions Total Hospital-Days
Median Length of
Stay
Placebo Pravastatin Placebo Pravastatin Plabeco Pravastatin Placebo Pravastatin
Cardiovascular
Atherosclerotic CHD 16.9 (17.1) 11.8 (11.0) 28.9 (28.8) 19.5 (17.8) 182 (184) 121 (116) 8 (8) 8 (8)
Other cardiac 2.5 (2.2) 2.1 (1.6) 3.0 (2.7) 2.6 (1.8) 29.4 (32.7) 17.8 (9.4) 5 (5) 5 (5)
Cerebrovascular 2.9 (2.7) 2.6 (2.2) 3.4 (3.2) 2.9 (2.4) 64.1 (55.8) 79.4 (49.8) 7 (7) 7 (7.5)
Other vascular 6.4 (6.8) 6.0 (5.4) 9.1 (10.0) 8.5 (7.1) 55.7 (62.0) 38.5 (28.8) 3 (2) 3.5 (3)
Total Cardiovascular 26.0 (26.1) 20.5 (18.8) 44.3 (44.7) 33.6 (29.1) 331 (335) 257 (204) 8 (8) 7 (7)
Noncardiovascular
Malignancy 6.2 (4.7) 6.3 (4.4) 15.7 (8.1) 14.3 (8.8) 143 (78.5) 125 (71.3) 14 (11) 13 (11.5)
Trauma 4.6 (4.7) 4.6 (4.5) 4.8 (5.0) 5.0 (4.8) 24.2 (24.0) 19.9 (19.8) 3 (3) 2 (2)
Psychiatric 2.2 (1.8) 1.8 (2.0) 3.4 (2.8) 2.2 (2.5) 76.8 (76.6) 56.1 (36.5) 8 (8) 8 (8)
Other 46.9 (44.7) 47.2 (44.1) 75.2 (67.4) 75.0 (68.3) 451 (367) 401 (326) 4 (4) 4 (4)
Any non-CVS 55.1 (52.4) 54.6 (50.4) 99.1 (83.4) 96.4 (84.5) 696 (546) 602 (453) 5 (5) 5 (4)
Any hospitalization 70.8 (68.9) 67.9 (63.1) 144 (128) 130 (114) 1027 (881) 858 (657) 7 (6) 6 (5)
Data are presented on number of subjects admitted to hospital, number of admissions and total hospital-days per 1,000 subject-years by treatment group. In addition, the median
length of stay (days) for all admissions is presented. For each category, values are given for all randomized subjects, with data for compliant subjects in parentheses. See text for
details.
Plac 5 placebo; Prav 5 pravastatin; CHD 5 coronary heart disease; CVS 5 cardiovascular.
Figure 1. Kaplan-Meier plots of time to first hospitalization by
treatment group for (a) cardiovascular and (b) noncardiovascular
trial categories. Log-rank p-values are given for the test of equality
of survival curves between the treatment groups.
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tween the pravastatin- and placebo-treated groups were
small reductions in the rates of admission for hepatobiliary
and dermatologic causes. The former may reflect in part the
beneficial effect of statins on bile lithogenicity (14,15).
Number of hospital bed-days. Among participants who
were hospitalized, no significant difference was seen in the
median duration of hospital admission between those
treated with pravastatin and the placebo in any diagnostic
category (Table 1). The 736 patients hospitalized for car-
diovascular causes occupied a total of 9,306 hospital bed
days (median 7, IQR 3 to 13, range 1 to 520), which
represented 31% of the 29,851 hospital-days for all causes.
Pravastatin treatment reduced the number of hospital bed-
days for CHD by 61.4 per 1,000 subject-years (95% CI 25.2
to 97.5, p 5 0.001), but there was no influence on the
number of bed-days for other cardiovascular diagnoses. The
number of bed-days for noncardiovascular causes was re-
duced by 94 per 1,000 subject-years (95% CI 264.8 to
252.6, p 5 0.28) in the pravastatin-treated group. This
resulted in a nonsignificant overall reduction in hospital bed
usage of 168.7 per 1,000 subject-years (95% CI 218.9 to
356.3, p 5 0.086) in the pravastatin-treated group.
Effect of pravastatin therapy in compliant subjects. For
the participants with $75% compliance, there were 11,697
treatment-years of follow-up on 2,452 placebo-treated sub-
jects, and 11,765 treatment-years on 2,450 pravastatin-
treated individuals. Pravastatin treatment reduced the risk of
compliant participants requiring hospital admission for
atherosclerotic CHD by 35% (95% CI 19 to 47, p ,
0.0001) and for all cardiovascular causes by 27% (95% CI 15
to 38, p 5 0.0001). The number of compliant patients
requiring hospital admission, the total number of admis-
sions, the total hospital bed-days and the median length of
stay are given in parentheses in Table 1. Compliant partic-Ta
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Figure 2. Effect of pravastatin on noncardiovascular hospital
admissions by ICD 8 Body System Code. The point estimate is
indicated by a diamond for the difference between placebo and
pravastatin groups in the mean number of admissions/1,000
subject-years. Negative values indicate reduction in hospitalization
in pravastatin-treated subjects. Approximate 95% CIs with per-
mutation p-value are indicated.
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ipants receiving the placebo had rates of hospitalization for
cardiovascular causes that were similar to the total cohort,
but had markedly lower rates of admission for malignancy
and other noncardiovascular diagnoses. This is likely to be
explained by the tendency of participants to discontinue
preventive therapy for CHD in the event of diagnosis of an
alternative life-threatening illness.
Effect of baseline risk. The number of hospital admissions
for cardiovascular and noncardiovascular causes according to
quartiles of baseline risk of the primary trial end point
(definite CHD death or nonfatal MI) is illustrated in Figure
3. Pravastatin therapy resulted in reductions in cardiovas-
cular hospitalizations in all quartiles of risk, with no evi-
dence of a differential effect of treatment across the quar-
tiles. The risk of noncardiovascular hospital admission also
increased progressively from quartile 1 to quartile 4, but
there was no trend towards any difference in noncardiovas-
cular events between treatment groups.
DISCUSSION
Effect of pravastatin on hospital admissions. The data on
hospitalization extend the principal results of the
WOSCOPS in indicating that pravastatin treatment in
middle-aged men with hypercholesterolemia substantially
reduces the probability of hospital admission for cardiovas-
cular causes. The effects noted here are largely attributable
to the effect of pravastatin in reducing the relative risk of
fatal CHD or nonfatal MI by 31% and coronary revascu-
larization by 37% (1). As expected, the compliant subgroup
showed a stronger treatment effect on cardiovascular hospi-
talizations than that seen for all participants.
Unlike the report of the primary end points of the trial,
based on a “time to first event” analysis, the current results
permit assessment of the effect of pravastatin on the overall
requirement for hospital admissions during the average
five-year follow-up of the trial. By including the effects of
second and subsequent admissions, the number of hospital
admissions for analysis is nearly doubled. The effect of
pravastatin in reducing total cardiovascular admissions is not
offset by any increase in noncardiovascular hospitalizations.
However, in this primary prevention population, the reduc-
tion in cardiovascular hospitalizations was diluted by the
greater number of noncardiovascular events to the extent
that the overall requirement for hospital admission was not
significantly reduced, although a favorable trend was seen.
Duration of hospital stay. The results of our analysis differ
from those presented by the Scandinavian Simvastatin
Survival Study (SSSS) because we found no significant effect
of therapy on duration of hospital admission for CHD (16).
We also found the distribution of length of hospital stay to
be skewed and therefore undertook a nonparametric analysis
and expressed the duration of admission as the median
(IQR) and range. In contrast, the SSSS investigators re-
ported an “average” duration of hospital stay and used
parametric statistics, although they did not report whether
their data were normally distributed, nor how they dealt
statistically with multiple hospitalizations in the same par-
ticipant.
The analysis of hospital days takes into account the
number of hospital admissions as well as the duration of
admission. A powerful beneficial effect was noted in the
pravastatin-treated group in respect to cardiovascular dis-
eases. A nonsignificant reduction occurred in total hospital-
days for noncardiovascular causes in the pravastatin group,
resulting in a total reduction of 168.7 hospital-days per
1,000 subject-years for all diagnoses in the pravastatin-
treated group. There is no clear explanation for the reduc-
tion in the number of hospitals-days for noncardiovascular
causes in the pravastatin group. This analysis is influenced
by a small number of patients who had very prolonged
hospital admissions (.1 year) and should be viewed with
caution. However, this reduction might be attributable to
prevention of cardiovascular complications other than myo-
cardial infarction in subjects initially hospitalized for non-
cardiovascular causes.
Effect of baseline risk. The finding that hospital admis-
sions for cardiovascular causes were reduced by pravastatin
therapy across all quartiles of risk is as expected. Our
previous report had shown that the proportional effect of
pravastatin in reducing risk was similar regardless of the
baseline level of risk (13). The observation that the proba-
bility of noncardiovascular hospitalization also increased in
parallel with the cardiovascular risk may appear surprising at
Figure 3. Hospital admissions by treatment group for (A) cardio-
vascular and (B) noncardiovascular trial categories by quartiles of
baseline 5-year untreated risk of definite CHD death or nonfatal
MI. See text for details.
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first sight. However, it is explicable on the basis that the
subjects in the higher quartiles of cardiovascular risk tended
to be older and were more likely to be smokers, thus also
increasing their risk of noncardiovascular diseases such as
cancer and respiratory disease.
Conclusions. In summary, these results confirm the ben-
eficial effects of pravastatin therapy on reducing health care
costs attributable to hospital admission (17). They provide
further reassurance that therapy did not produce any adverse
effects on noncardiovascular events, particularly on cancers,
trauma and psychiatric hospitalizations.
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